Subcutaneous Progesterone Versus Vaginal Progesterone Tablets for Luteal Phase Support in In Vitro Fertilization (IVF)
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
Prospective, open, randomized, parallel, multicenter, two-arm trial to evaluate the efficacy
and tolerability of a new progesterone formulation to be used for luteal support in IVF
(Progesterone-IBSA) administered subcutaneously at a daily dose of 25 mg versus Progesterone
tablets administered intravaginally at 100 mg twice daily for a total dose of 200 mg.